Japanese

Today's pharmacotherapy for COVID-19 Motoki FUJII 1 , Yoshiro HAYASHI 2 1Department of Infection Disease Department of Intensive Care Medicine Kameda Medical Center 2Department of Intensive Care Medicine Kameda Medical Center pp.515-537
Published Date 2021/7/1
DOI https://doi.org/10.11477/mf.3102200890
  • Abstract
  • Look Inside
  • Reference

Pharmacotherapy for COVID-19 can be classified into antiviral,anti-inflammatory,and anticoagulant therapy. As a result of the understanding of the pathogenesis of COVID-19 and numerous clinical studies,pharmacotherapies have been gradually established. However,as of May 2021,only dexamethasone and tocilizumab have been shown to reduce mortality in large RCTs. Therefore,drugs approved for COVID-19 in Japan are minimal,with only remdesivir,dexamethasone,and baricitinib. In this article,we will review the clinical evidence for each drug and describe the pharmacotherapy according to the severity of the disease.


Copyright © 2021, MEDICAL SCIENCES INTERNATIONAL, LTD. All rights reserved.

基本情報

電子版ISSN 2186-7852 印刷版ISSN 1883-4833 メディカル・サイエンス・インターナショナル

関連文献

もっと見る

文献を共有